Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.26)
# 438
Out of 4,911 analysts
234
Total ratings
42.06%
Success rate
20.11%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Initiates: Overweight | $11 | $5.50 | +100.00% | 1 | Jul 24, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $25 → $29 | $11.47 | +152.83% | 3 | Jul 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Overweight | $74 | $44.60 | +65.92% | 1 | Jul 7, 2025 | |
| SLDB Solid Biosciences | Assumes: Overweight | $16 | $6.56 | +143.90% | 1 | May 22, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Overweight | $10 | $7.79 | +28.37% | 4 | May 15, 2025 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $30 | $6.70 | +347.76% | 6 | May 14, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $113 → $112 | $45.10 | +148.34% | 19 | May 7, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $23 | $20.33 | +13.16% | 7 | May 7, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $163 → $81 | $12.17 | +565.57% | 16 | May 7, 2025 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.56 | +173.44% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $88.29 | +39.31% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $1.70 | +5,209.73% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $1.76 | +297.73% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $132 | $60.30 | +118.92% | 8 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $18.16 | +37.67% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $27.19 | +334.06% | 18 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 | $32.64 | +10.29% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $22.86 | +193.15% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $6.09 | +244.83% | 7 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $9.68 | +199.59% | 13 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.11 | +313.63% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.48 | +440.54% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $58 | $15.08 | +284.62% | 9 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $3.04 | +261.84% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $6.46 | +178.64% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $3.86 | +262.69% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.45 | +430.61% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.85 | +1,034.71% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.20 | +400.00% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $2.01 | +895.02% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $3.02 | +661.59% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $2.00 | +44,900.00% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.55 | +7,346.42% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $3.90 | +10,156.41% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $0.73 | +11,504.10% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $7.29 | +2,370.83% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.11 | +3,956.25% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.09 | +913.82% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.48 | +3,953.51% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.29 | +6,876.74% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $2.07 | +121,933.90% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.44 | +36,181.18% | 1 | Jan 9, 2020 |
Eupraxia Pharmaceuticals
Jul 24, 2025
Initiates: Overweight
Price Target: $11
Current: $5.50
Upside: +100.00%
Zevra Therapeutics
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $11.47
Upside: +152.83%
Monopar Therapeutics
Jul 7, 2025
Initiates: Overweight
Price Target: $74
Current: $44.60
Upside: +65.92%
Solid Biosciences
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $6.56
Upside: +143.90%
Fulcrum Therapeutics
May 15, 2025
Upgrades: Overweight
Price Target: $10
Current: $7.79
Upside: +28.37%
Capricor Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $6.70
Upside: +347.76%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $113 → $112
Current: $45.10
Upside: +148.34%
Rigel Pharmaceuticals
May 7, 2025
Maintains: Neutral
Price Target: $20 → $23
Current: $20.33
Upside: +13.16%
Sarepta Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $12.17
Upside: +565.57%
Taysha Gene Therapies
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $2.56
Upside: +173.44%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $88.29
Upside: +39.31%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $1.70
Upside: +5,209.73%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $1.76
Upside: +297.73%
Mar 18, 2025
Maintains: Overweight
Price Target: $99 → $132
Current: $60.30
Upside: +118.92%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.16
Upside: +37.67%
Feb 26, 2025
Reiterates: Overweight
Price Target: $118
Current: $27.19
Upside: +334.06%
Feb 26, 2025
Reiterates: Neutral
Price Target: $36
Current: $32.64
Upside: +10.29%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $22.86
Upside: +193.15%
Jan 15, 2025
Reiterates: Overweight
Price Target: $21
Current: $6.09
Upside: +244.83%
Jan 2, 2025
Reiterates: Overweight
Price Target: $29
Current: $9.68
Upside: +199.59%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.11
Upside: +313.63%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $1.48
Upside: +440.54%
Dec 10, 2024
Maintains: Overweight
Price Target: $28 → $58
Current: $15.08
Upside: +284.62%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $3.04
Upside: +261.84%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $6.46
Upside: +178.64%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $3.86
Upside: +262.69%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $2.45
Upside: +430.61%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.85
Upside: +1,034.71%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.20
Upside: +400.00%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $2.01
Upside: +895.02%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $3.02
Upside: +661.59%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $2.00
Upside: +44,900.00%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.55
Upside: +7,346.42%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $3.90
Upside: +10,156.41%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $0.73
Upside: +11,504.10%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $7.29
Upside: +2,370.83%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.11
Upside: +3,956.25%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.09
Upside: +913.82%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.48
Upside: +3,953.51%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.29
Upside: +6,876.74%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $2.07
Upside: +121,933.90%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.44
Upside: +36,181.18%